Research progress of JAK1/2 inhibitors in the treatment of myeloproliferative neoplasms
10.3760/cma.j.issn.1009-9921.2015.07.006
- VernacularTitle:JAK1/2抑制剂治疗骨髓增殖性肿瘤的研究进展
- Author:
Shuhao MEI
;
Jin LU
- Publication Type:Journal Article
- Keywords:
Myeloproliferative neoplasms;
Polyeythemia vera;
Primary myelofibrosis;
Ruxolitinib
- From:
Journal of Leukemia & Lymphoma
2015;24(7):405-407,411
- CountryChina
- Language:Chinese
-
Abstract:
The bcr-abl negative myeloproliferative neoplasms (MPN) include polycythemia vera (PV),essential thrombocythemia (ET) and primary myelofibrosis (PMF).Along with the detecting of JAK2 V617F gene mutation in MPN patients,a series of small molecules drugs that targeted to the mutation have been investigated in clinical trials.Ruxolitinib is the inhibitor of JAK1/2,which has been proved by USA Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to treat patients with intermediate-2 or high-risk PMF or post-PV MF or post-ET MF and PV patients who are intolerant or resistant to hydroxycarbamide,attributed to a number of clinical trials,especially in COMFORT-Ⅰ and COMFORT-Ⅱ.As a result,the MPN patients have new hope for the treatment.
